Logo

American Heart Association

  2
  0


Final ID: MDP1360

A novel Urocortin-2 analog COR-1167 corrects cardiac and renal dysfunction on top of Empagliflozin in a rat model of acute decompensated heart failure

Abstract Body (Do not enter title and authors here): Introduction: Urocortin-2 (UCN-2) is a peptide belonging to the corticotropin-releasing factor family that has cardiovascular, renal, metabolic and anti-inflammatory actions and improves cardiac function in human heart failure (HF) and cardiorenal dysfunction in chronic HF models. However, UCN-2 has a short half-life and intravenous delivery limits its therapeutic use. COR-1167 was discovered as a stable UCN-2 analog with qd pharmacological effects when injected subcutaneously.
Hypothesis: Whether COR-1167 exerts chronic cardiorenal protection in Acute Decompensated HF (ADHF) is unknown, and in particular on background of SGLT2 inhibition, therefore both treatments were tested in a rat model of ADHF.
Methods: Rats had coronary artery ligation to induce MI and a reduced ejection fraction phenotype. Three months later, rats were treated with vehicle or Empagliflozin (Empa) at 10 mg/kg/day PO. One month after starting Empa, two acute decompensation events were induced by administrating NaCl solution (1.8 g/kg, PO) on Day 0 and Day 14. Empa treated ADHF rats received vehicle or COR-1167 (3 µg/kg/day) by SC injections starting at 12 hours after the first decompensation and all treatments continued for 14 days. The groups were ADHF, ADHF + Empa and ADHF + Empa + COR-1167 (n=7-10/group). Left ventricular (LV) hemodynamics (cardiac catheters), cardiac output (echocardiography) and LV tissue perfusion (magnetic resonance imaging), cardiac mitochondrial coupling and ATP production (Seahorse) were measured 1 day after the second decompensation, while urine volume (uVol) and urine Na+ excretion (uNa+) collected from metabolic cages were analyzed 7 days after the first decompensation.
Results: Compared to ADHF control rats, Empa treatment had no effect on systolic blood pressure (SBP), cardiac output (CO), LV end systolic pressure volume relationship (LVESPVR), LV end diastolic pressure volume relationship (LVEDPR), mitochondrial coupling and ATP production, but it increased myocardial perfusion, uVol and uNa+ excretion. Compared to ADHF + Empa rats, COR-1167 treatment increased SBP, CO, LVESPVR, myocardial perfusion, mitochondrial coupling and ATP production, uVol, uNa+, while decreasing LVEDPVR.
Conclusion: In the setting of ADHF, significant cardiorenal benefits and decongestion occurred when COR-1167 was administered on top of an SGLT2 inhibitor.
  • Stephan, Yohan  ( INSERM U1096 , Rouen , France )
  • Corruble, Clement  ( INSERM U1096 , Rouen , France )
  • Charrier, Lucie  ( INSERM U1096 , Rouen , France )
  • Nicol, Lionel  ( INSERM U1096 , Rouen , France )
  • Kowala, Mark  ( Corteria Pharmaceuticals , Paris , France )
  • Ozoux, Marie-laure  ( Corteria Pharmaceuticals , Paris , France )
  • Lawson, Francesca  ( Corteria Pharmaceuticals , Paris , France )
  • Janiak, Philip  ( Corteria Pharmaceuticals , Paris , France )
  • Mulder, Paul  ( INSERM U1096 , Rouen , France )
  • Author Disclosures:
    Yohan Stephan: DO NOT have relevant financial relationships | Clement Corruble: DO NOT have relevant financial relationships | Lucie Charrier: No Answer | Lionel NICOL: No Answer | Mark Kowala: DO have relevant financial relationships ; Consultant:Corteria Pharmaceuticals:Active (exists now) | Marie-Laure Ozoux: DO have relevant financial relationships ; Employee:Corteria Pharmaceuticals:Active (exists now) | Francesca Lawson: No Answer | Philip Janiak: DO have relevant financial relationships ; Executive Role:Corteria Pharamceuticals:Active (exists now) | Paul Mulder: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

SGLT-2 Inhibition in Heart Failure: Beyond the RCTs. What Else Do We Know?

Monday, 11/18/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen

Yan Jing-he, Taylor Amanda, Clough Timothy, Burmeister Getz Elise, Pazdirkova Marketa, Russo Cesare

Effect of Sacubitril/Valsartan in Patients with Concomitant Heart Failure with Reduced Ejection Fraction and End-Stage Renal Disease on Hemodialysis

Ahn Yuran, Jung Mi-hyang, Youn Jong-chan, Cho Dong-hyuk, Choi Jimi, Yoo Byung-su

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available